{"id":68666,"date":"2026-06-22T20:07:03","date_gmt":"2026-06-22T12:07:03","guid":{"rendered":"https:\/\/flcube.com\/?p=68666"},"modified":"2026-06-22T20:07:04","modified_gmt":"2026-06-22T12:07:04","slug":"sunshine-lake-pharma-advances-novel-ly6g6d-4-1bb-bispecific-antibody-hec-921-toward-phase-i-clinical-trials-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68666","title":{"rendered":"Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sunshine Lake Pharma Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6887:HKG\">HKG: 6887<\/a>) announced that its investigational new drug application for <strong>HEC-921<\/strong>, a <strong>first-in-class bispecific antibody (BsAb)<\/strong> targeting <strong>LY6G6D and 4-1BB<\/strong>, is under active review by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, with <strong>Phase I clinical trials<\/strong> expected to commence upon approval. The molecule represents a novel approach to tumor-targeted immune activation with no similar products filed globally to date.<\/p>\n\n\n\n<h2 id=\"h-development-amp-regulatory-status\" class=\"wp-block-heading\">Development &amp; Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Developer<\/strong><\/td><td>Sunshine Lake Pharma (China)<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>Bispecific antibody (BsAb)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>LY6G6D (tumor antigen) + 4-1BB (immune co-stimulatory receptor)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>IND under NMPA review<\/td><\/tr><tr><td><strong>Planned Study<\/strong><\/td><td>Phase I clinical trial<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>First-in-class; no similar products filed worldwide<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-mechanism-of-action-amp-innovation\" class=\"wp-block-heading\">Mechanism of Action &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tumor-Targeted Immune Activation:<\/strong> Utilizes <strong>LY6G6D<\/strong> as a tumor-specific anchor to achieve selective enrichment within tumor tissue<\/li>\n\n\n\n<li><strong>Localized 4-1BB Stimulation:<\/strong> Activates the <strong>4-1BB pathway<\/strong> exclusively within the tumor microenvironment, minimizing systemic toxicity associated with traditional 4-1BB agonists<\/li>\n\n\n\n<li><strong>Dual-Action Design:<\/strong> Simultaneously delivers tumor targeting and immune co-stimulation through a single molecular entity<\/li>\n\n\n\n<li><strong>Safety Optimization:<\/strong> Tumor-restricted 4-1BB activation addresses historical safety concerns that have limited development of systemic 4-1BB agonists<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-market-opportunity\" class=\"wp-block-heading\">Competitive Landscape &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>4-1BB Therapeutic Challenge:<\/strong> Despite strong preclinical efficacy, systemic 4-1BB agonists have faced clinical setbacks due to liver toxicity and cytokine release syndrome<\/li>\n\n\n\n<li><strong>LY6G6D Target Profile:<\/strong> Expressed predominantly on gastrointestinal and other solid tumors, providing a favorable therapeutic window for targeted delivery<\/li>\n\n\n\n<li><strong>First-Mover Advantage:<\/strong> As the first LY6G6D\/4-1BB bispecific globally, Sunshine Lake Pharma could establish dominant intellectual property position in this novel mechanism<\/li>\n\n\n\n<li><strong>Solid Tumor Focus:<\/strong> Addresses high-unmet-need indications including colorectal, gastric, and pancreatic cancers where LY6G6D expression has been validated<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This filing positions <strong>Sunshine Lake Pharma<\/strong> at the forefront of <strong>next-generation bispecific antibody<\/strong> development in China, demonstrating the company&#8217;s capability to innovate beyond biosimilars into novel target combinations. The tumor-targeted immune activation approach represents a sophisticated solution to the historical challenges of 4-1BB pathway therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts note that successful clinical validation could attract significant partnership interest from global pharmaceutical companies seeking differentiated immuno-oncology assets with improved safety profiles. The Chinese biotech sector&#8217;s increasing focus on novel mechanisms rather than me-too approaches is exemplified by HEC-921&#8217;s innovative design.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and competitive positioning. Actual results may differ due to regulatory decisions, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061801787_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061801787_c.\"><\/object><a id=\"wp-block-file--media-26d73df2-a8b6-4325-a222-df6707a2eab9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061801787_c.pdf\">2026061801787_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061801787_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-26d73df2-a8b6-4325-a222-df6707a2eab9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its investigational new drug application for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[90,4190,28,2054],"class_list":["post-68666","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-filings","tag-hkg-6887","tag-multi-specific-antibodies","tag-sunshine-lake-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its investigational new drug application for HEC-921, a first-in-class bispecific antibody (BsAb) targeting LY6G6D and 4-1BB, is under active review by China&#039;s National Medical Products Administration (NMPA), with Phase I clinical trials expected to commence upon approval. The molecule represents a novel approach to tumor-targeted immune activation with no similar products filed globally to date.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68666\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China\" \/>\n<meta property=\"og:description\" content=\"Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its investigational new drug application for HEC-921, a first-in-class bispecific antibody (BsAb) targeting LY6G6D and 4-1BB, is under active review by China&#039;s National Medical Products Administration (NMPA), with Phase I clinical trials expected to commence upon approval. The molecule represents a novel approach to tumor-targeted immune activation with no similar products filed globally to date.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68666\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T12:07:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T12:07:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68666#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68666\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sunshine Lake Pharma Advances Novel LY6G6D\\\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China\",\"datePublished\":\"2026-06-22T12:07:03+00:00\",\"dateModified\":\"2026-06-22T12:07:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68666\"},\"wordCount\":438,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial filings\",\"HKG: 6887\",\"Multi-specific antibodies\",\"Sunshine Lake Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68666#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68666\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68666\",\"name\":\"Sunshine Lake Pharma Advances Novel LY6G6D\\\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-22T12:07:03+00:00\",\"dateModified\":\"2026-06-22T12:07:04+00:00\",\"description\":\"Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its investigational new drug application for HEC-921, a first-in-class bispecific antibody (BsAb) targeting LY6G6D and 4-1BB, is under active review by China's National Medical Products Administration (NMPA), with Phase I clinical trials expected to commence upon approval. The molecule represents a novel approach to tumor-targeted immune activation with no similar products filed globally to date.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68666#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68666\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68666#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sunshine Lake Pharma Advances Novel LY6G6D\\\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry","description":"Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its investigational new drug application for HEC-921, a first-in-class bispecific antibody (BsAb) targeting LY6G6D and 4-1BB, is under active review by China's National Medical Products Administration (NMPA), with Phase I clinical trials expected to commence upon approval. The molecule represents a novel approach to tumor-targeted immune activation with no similar products filed globally to date.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68666","og_locale":"en_US","og_type":"article","og_title":"Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China","og_description":"Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its investigational new drug application for HEC-921, a first-in-class bispecific antibody (BsAb) targeting LY6G6D and 4-1BB, is under active review by China's National Medical Products Administration (NMPA), with Phase I clinical trials expected to commence upon approval. The molecule represents a novel approach to tumor-targeted immune activation with no similar products filed globally to date.","og_url":"https:\/\/flcube.com\/?p=68666","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-22T12:07:03+00:00","article_modified_time":"2026-06-22T12:07:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68666#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68666"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China","datePublished":"2026-06-22T12:07:03+00:00","dateModified":"2026-06-22T12:07:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68666"},"wordCount":438,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial filings","HKG: 6887","Multi-specific antibodies","Sunshine Lake Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68666#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68666","url":"https:\/\/flcube.com\/?p=68666","name":"Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-22T12:07:03+00:00","dateModified":"2026-06-22T12:07:04+00:00","description":"Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its investigational new drug application for HEC-921, a first-in-class bispecific antibody (BsAb) targeting LY6G6D and 4-1BB, is under active review by China's National Medical Products Administration (NMPA), with Phase I clinical trials expected to commence upon approval. The molecule represents a novel approach to tumor-targeted immune activation with no similar products filed globally to date.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68666#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68666"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68666#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sunshine Lake Pharma Advances Novel LY6G6D\/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68666"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68666\/revisions"}],"predecessor-version":[{"id":68668,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68666\/revisions\/68668"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}